Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

biolife solutions - BLFS

BLFS

Close Chg Chg %
24.95 -0.09 -0.36%

Closed Market

24.86

-0.09 (0.36%)

Volume: 229.63K

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Trade Now

Company Overview: biolife solutions - BLFS

BLFS Key Data

Open

$24.96

 Day Range

24.36 - 25.18

52 Week Range

19.15 - 29.57

 Market Cap

$1.22B

Shares Outstanding

48.15M

 Public Float

46.44M

Beta

1.93

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.06

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

320.99K

  

BLFS Performance

1 Week
 
 4.06%
 
1 Month
 
 1.93%
 
3 Months
 
 -7.24%
 
1 Year
 
 -6.58%
 
5 Years
 
 -39.07%
 

BLFS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About biolife solutions - BLFS

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

BLFS At a Glance

BioLife Solutions, Inc.
3303 Monte Villa Parkway
Bothell, Washington 98021
Phone 1-425-402-1400 Revenue 82.25M
Industry Medical Specialties Net Income -36,061,000.00
Sector Health Technology Employees 159
Fiscal Year-end 12 / 2025
View SEC Filings

BLFS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 14.539
Price to Book Ratio 3.49
Price to Cash Flow Ratio 141.85
Enterprise Value to EBITDA -684.671
Enterprise Value to Sales 13.634
Total Debt to Enterprise Value 0.027

BLFS Efficiency

Revenue/Employee 517,320.755
Income Per Employee -226,798.742
Receivables Turnover 8.972
Total Asset Turnover 0.201

BLFS Liquidity

Current Ratio 4.545
Quick Ratio 3.658
Cash Ratio 3.195

BLFS Profitability

Gross Margin 61.923
Operating Margin -8.667
Pretax Margin -13.89
Net Margin -43.841
Return on Assets -2.787
Return on Equity -3.317
Return on Total Capital -3.004
Return on Invested Capital -3.09

BLFS Capital Structure

Total Debt to Total Equity 8.648
Total Debt to Total Capital 7.96
Total Debt to Total Assets 7.462
Long-Term Debt to Equity 5.079
Long-Term Debt to Total Capital 4.674
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biolife Solutions - BLFS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
119.16M 161.76M 143.27M 82.25M
Sales Growth
+147.79% +35.75% -11.43% -42.59%
Cost of Goods Sold (COGS) incl D&A
90.31M 117.63M 101.70M 31.32M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
15.05M 19.96M 12.29M 5.49M
Depreciation
6.85M 10.26M 7.11M 2.75M
Amortization of Intangibles
8.20M 9.70M 5.18M 2.74M
COGS Growth
+281.39% +30.26% -13.55% -69.20%
Gross Income
28.85M 44.13M 41.57M 50.93M
Gross Income Growth
+18.18% +52.97% -5.79% +22.52%
Gross Profit Margin
+24.21% +27.28% +29.02% +61.92%
2021 2022 2023 2024 5-year trend
SG&A Expense
58.27M 84.04M 99.10M 58.06M
Research & Development
11.82M 14.80M 18.80M 7.91M
Other SG&A
46.45M 69.24M 80.31M 50.15M
SGA Growth
+110.08% +44.21% +17.93% -41.41%
Other Operating Expense
- - - -
-
Unusual Expense
(1.82M) 104.93M 13.29M 4.07M
EBIT after Unusual Expense
(27.61M) (144.84M) (70.83M) (11.20M)
Non Operating Income/Expense
289.00K 704.00K 6.38M 497.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
432.00K 687.00K 1.81M 719.00K
Interest Expense Growth
- +59.03% +163.76% -60.32%
Gross Interest Expense
432.00K 687.00K 1.81M 719.00K
Interest Capitalized
- - - -
-
Pretax Income
(27.75M) (144.83M) (66.26M) (11.43M)
Pretax Income Growth
-4,548.74% -421.84% +54.25% +82.76%
Pretax Margin
-23.29% -89.53% -46.25% -13.89%
Income Tax
(20.12M) (5.02M) 169.00K (38.00K)
Income Tax - Current - Domestic
- 11.00K 46.00K 26.00K
Income Tax - Current - Foreign
- 9.00K 205.00K 185.00K
Income Tax - Deferred - Domestic
(20.13M) (5.24M) (62.00K) (64.00K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(7.63M) (139.81M) (66.43M) (11.39M)
Minority Interest Expense
- - - -
-
Net Income
(7.63M) (139.81M) (66.43M) (11.39M)
Net Income Growth
-386.28% -1,731.11% +52.49% +82.86%
Net Margin Growth
-6.41% -86.43% -46.36% -13.84%
Extraordinaries & Discontinued Operations
- - - (24.67M)
-
Discontinued Operations
- - - (24.67M)
-
Net Income After Extraordinaries
(7.63M) (139.81M) (66.43M) (36.06M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(7.63M) (139.81M) (66.43M) (36.06M)
EPS (Basic)
-0.1983 -3.291 -1.5194 -0.7828
EPS (Basic) Growth
-321.07% -1,559.61% +53.83% +48.48%
Basic Shares Outstanding
38.50M 42.48M 43.72M 46.07M
EPS (Diluted)
-0.1983 -3.291 -1.5194 -0.7828
EPS (Diluted) Growth
-468.19% -1,559.61% +53.83% +48.48%
Diluted Shares Outstanding
38.50M 42.48M 43.72M 46.07M
EBITDA
(14.37M) (19.95M) (45.24M) (1.64M)
EBITDA Growth
-681.24% -38.83% -126.70% +96.38%
EBITDA Margin
-12.06% -12.34% -31.58% -1.99%

Snapshot

Average Recommendation BUY Average Target Price 32.10
Number of Ratings 10 Current Quarters Estimate 0.014
FY Report Date 03 / 2026 Current Year's Estimate 0.10
Last Quarter’s Earnings -0.01 Median PE on CY Estimate N/A
Year Ago Earnings -0.337 Next Fiscal Year Estimate 0.33
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 8 3
Mean Estimate 0.01 0.02 0.10 0.33
High Estimates 0.05 0.04 0.16 0.42
Low Estimate -0.02 -0.01 0.03 0.25
Coefficient of Variance 150.44 76.38 45.45 25.89

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 10 10
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Biolife Solutions - BLFS

Date Name Shares Transaction Value
Nov 17, 2025 Roderick de Greef President and CEO; Director 421,163 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.88 per share 10,899,698.44
Nov 17, 2025 Roderick de Greef President and CEO; Director 389,998 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.33 per share 9,878,649.34
Nov 17, 2025 Roderick de Greef President and CEO; Director 454,581 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $26.15 per share 11,887,293.15
Jul 10, 2025 Troy Wichterman Chief Financial Officer 185,808 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.27 per share 4,137,944.16
Jul 10, 2025 Sarah Aebersold Chief Human Resources Officer 78,523 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.27 per share 1,748,707.21
Jul 10, 2025 Karen Foster Chief Quality and Operations 194,596 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.27 per share 4,333,652.92
Jul 10, 2025 Todd Berard Chief Marketing Officer 134,618 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.27 per share 2,997,942.86
Jul 10, 2025 Aby J. Mathew EVP & Chief Scientific Officer 352,582 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.27 per share 7,852,001.14
Mar 21, 2025 Sean Werner Chief Technology Officer 27,784 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Troy Wichterman Chief Financial Officer 214,929 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Rachel H. Ellingson Director 49,825 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Aby J. Mathew EVP & Chief Scientific Officer 320,165 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Tony J. Hunt Director 6,876 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Amy DuRoss Director 30,687 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Todd Berard Chief Marketing Officer 144,858 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Amy DuRoss Director 23,811 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.96 per share 594,322.56
Mar 21, 2025 Karen Foster Chief Quality and Operations 203,722 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Catherine Havlik Coste Director 5,701 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Joydeep Goswami Director 47,986 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Sarah Aebersold Chief Human Resources Officer 85,865 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Biolife Solutions in the News